Antimonial drugs entrapped into phosphatidylserine liposomes: physicochemical evaluation and antileishmanial activity
Tóm tắt
Từ khóa
Tài liệu tham khảo
Alvar J, 2012, Leishmaniasis worldwide and global estimates of its incidence, PLoS One, 7, 10.1371/journal.pone.0035671
Desjeux P, 2004, Leishmaniasis: current situation and new perspectives, Comp Immunol Microbiol Infect Dis, 27, 305, 10.1016/j.cimid.2004.03.004
McGwire BS, 2014, Leishmaniasis: clinical syndromes and treatment, QJM, 107, 7, 10.1093/qjmed/hct116
Frézard F, 2010, New delivery strategies for the old pentavalent antimonial drugs, Expert Opin Drug Deliv, 7, 1343, 10.1517/17425247.2010.529897
Peine KJ, 2014, Liposomal resiquimod for the treatment of Leishmania donovani infection, J Antimicrob Chemother, 69, 168, 10.1093/jac/dkt320
Schettini DA, 2006, Improved targeting of antimony to the bone marrow of dogs using liposomes of reduced size, Int J Pharm, 315, 140, 10.1016/j.ijpharm.2006.01.048
Alving CR, 1986, Liposomes as drug carriers in leishmaniasis and malaria, Parasitol Today, 2, 101, 10.1016/0169-4758(86)90039-6
Carter KC, 1989, Visceral leishmaniasis: drug carrier system characteristics and the ability to clear parasites from the liver, spleen and bone marrow in Leishmania donovani infected BALB/c mice, J Pharm Pharmacol, 41, 87, 10.1111/j.2042-7158.1989.tb06399.x
New RR, 1980, Treatment of experimental cutaneous leishmaniasis by liposome-entrapped Pentostam, Acta Trop, 37, 253
Frézard F, 2009, Pentavalent antimonials: new perspectives for old drugs, Molecules, 14, 2317, 10.3390/molecules14072317
Schwendener RA, 1984, The effects of charge and size on the interaction of unilamellar liposomes with macrophages, Biochim Biophys Acta, 772, 93, 10.1016/0005-2736(84)90521-2
Borborema SET, 2011, Uptake and antileishmanial activity of meglumine antimoniate-containing liposomes in Leishmania (Leishmania) major-infected macrophages, Int J Antimicrob Agents, 38, 341, 10.1016/j.ijantimicag.2011.05.012
Tempone AG, 2004, Targeting Leishmania (L.) chagasi amastigotes through macrophage scavenger receptors: the use of drugs entrapped in liposomes containing phosphatidylserine, J Antimicrob Chemother, 54, 60, 10.1093/jac/dkh281
Tempone AG, 2005, Synthesis and antileishmanial activities of novel 3-substituted quinolines, Antimicrob Agents Chemother, 49, 1076, 10.1128/AAC.49.3.1076-1080.2005
Stewart JC, 1980, Colorimetric determination of phospholipids with ammonium ferrothiocyanate, Anal Biochem, 104, 10, 10.1016/0003-2697(80)90269-9
Tada H, 1986, An improved colorimetric assay for interleukin 2, J Immunol Methods, 93, 157, 10.1016/0022-1759(86)90183-3
Roberts WL, 1995, In vitro antileishmanial properties of tri-and pentavalent antimonial preparations, Antimicrob Agents Chemother, 39, 1234, 10.1128/AAC.39.6.1234
Dey T, 2000, Antileishmanial activities of stearylamine-bearing liposomes, Antimicrob Agents Chemother, 44, 1739, 10.1128/AAC.44.6.1739-1742.2000
Banerjee A, 2008, Stearylamine-bearing cationic liposomes kill Leishmania parasites through surface exposed negatively charged phosphatidylserine, J Antimicrob Chemother, 61, 103, 10.1093/jac/dkm396
Papagiannaros A, 2005, Antileishmanial and trypanocidal activities of new miltefosine liposomal formulations, Biomed Pharmacother, 59, 545, 10.1016/j.biopha.2005.06.011
Jaafari MR, 2009, Effect of topical liposomes containing paromomycin sulfate in the course of Leishmania major infection in susceptible BALB/c mice, Antimicrob Agents Chemother, 53, 2259, 10.1128/AAC.01319-08
Alving CR, 1978, Therapy of leishmaniasis: superior efficacies of liposome-encapsulated drugs, Proc Natl Acad Sci USA, 75, 2959, 10.1073/pnas.75.6.2959
Rothkopf C, 2005, Uptake of phosphatidylserine-containing liposomes by liver sinusoidal endothelial cells in the serum-free perfused rat liver, Biochim Biophys Acta, 1668, 10, 10.1016/j.bbamem.2004.10.013
Gilbreath MJ, 1986, Inhibition of lymphokine-induced macrophage microbicidal activity against Leishmania major by liposomes: characterization of the physicochemical requirements for liposome inhibition, J Immunol, 137, 681, 10.4049/jimmunol.137.5.1681
Alving CR, 1983, Delivery of liposome-encapsulated drugs to macrophages, Pharmacol Ther, 22, 407, 10.1016/0163-7258(83)90010-4
Jousma H, 1987, Characterization of liposomes. The influence of extrusion of multilamellar vesicles through polycarbonate membranes on particle size, particle size distribution and number of bilayers, Intern J Pharmaceutics, 35, 263, 10.1016/0378-5173(87)90139-6
Olson F, 1979, Preparation of liposomes of defined size distribution by extrusion through polycarbonate membranes, Biochim Biophys Acta, 557, 9, 10.1016/0005-2736(79)90085-3
Mayer LD, 1986, Techniques for encapsulating bioactive agents into liposomes, Chem Phys Lipids, 40, 333, 10.1016/0009-3084(86)90077-0
Castro RA, 2014, Association of liposome-encapsulated trivalent antimonial with ascorbic acid: an effective and safe strategy in the treatment of experimental visceral leishmaniasis, PLoS One, 9, 10.1371/journal.pone.0104055
Goldbach P, 1995, Sterile filtration of liposomes: Retention of encapsulated carboxyfluorescein, Int J Pharm, 117, 225, 10.1016/0378-5173(94)00346-7
Guo LS, 1980, Interaction of unilamellar liposomes with serum lipoproteins and apolipoproteins, J Lipid Res, 21, 993, 10.1016/S0022-2275(20)34759-3
Cullis PR, 1998, Interactions of liposomes and lipid-based carrier systems with blood proteins: Relation to clearance behaviour in vivo, Adv Drug Deliv Rev, 32, 3, 10.1016/S0169-409X(97)00128-2
Balasegaram M, 2012, Liposomal amphotericin B as a treatment for human leishmaniasis, Expert Opin Emerg Drugs, 17, 493, 10.1517/14728214.2012.748036